Markus Möhler

16PUBLICATIONS
134CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Tissue engineeringPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 23, 2026
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

Markus Moehler, Do-Youn Oh, Ken Kato

|Aug 14, 2024
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC.

Ho Yeong Lim, Jeong Heo, Julio A Peguero

|Jun 01, 2024
PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.

Samuel J Klempner, Eric S Cowden, Samuel L Cytryn

|Feb 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler

|Sep 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.

Markus Moehler, Hong Xiao, Steven I Blum

Pageof 3

Frequent Collaborators

3 joint publications

Roberto Pazo-Cid

3 joint publications

Fabian Bartsch

3 joint publications

Lucjan Wyrwicz

2 joint publications

Roman Kloeckner